BBIO
BridgeBio Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$66.61
−1.04%Sep 9, 2026, 14:30 UTC
BridgeBio Pharma announced new exploratory results from its Phase 3 PROPEL 3 trial of oral Infigratinib in children with achondroplasia, showing benefits beyond growth, and plans a potential U.S. launch in mid-2027.
Source:Aug 31, 2026, 19:14 UTC
President Donald J. Trump announced agreements with nine additional pharmaceutical manufacturers to lower drug prices for Americans in line with most-favored-nation pricing.
Aug 28, 2026, 09:23 UTC
AstraZeneca announced on Friday that its Phase 3 clinical trial for an experimental silencer drug in ATTR-CM patients failed to show additional benefit over existing stabilizer therapy, impacting its partnership with Ionis Pharmaceuticals and the broader market.
Aug 26, 2026, 11:30 UTC
BridgeBio announced that the first participant has been dosed in ASCEND-ATTR, a Phase 3b/4 study evaluating the long-term effects of acoramidis on disease regression in ATTR-CM.
Source:Aug 24, 2026, 11:30 UTC
BridgeBio Pharma announced that new acoramidis data from open-label extension analyses in ATTR-CM will be presented at the ESC Congress 2026 in Munich, Germany, on August 28-31, 2026.
Source:Aug 14, 2026, 00:35 UTC
KKR affiliate is selling BridgeBio Pharma shares at $78-$80 per share, as reported on August 13, 2026.
Aug 13, 2026, 21:42 UTC
BridgeBio Pharma announced the launch of a secondary public offering of 5,000,000 shares of its common stock by selling stockholder KKR Genetic Disorder L.P.; BridgeBio will not receive any proceeds.
Aug 10, 2026, 22:04 UTC
BridgeBio Pharma reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026.
Jul 22, 2026, 11:30 UTC
BridgeBio Pharma announced that the FDA accepted for filing its New Drug Application for encaleret for the treatment of autosomal dominant hypocalcemia type 1.
Source:Jul 1, 2026, 11:30 UTC
BridgeBio Pharma raised $1 billion in preferred equity financing led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, at an initial conversion price of approximately $138 per share.
Jun 26, 2026, 00:00 UTC
BridgeBio Pharma announced the departure of director Randal W. Scott and the election of directors James C. Momtazee, Frank P. McCormick, and Hannah A. Valantine, effective June 22, 2026.